EGFR and Miyoshi myopathy: The observation that MM cell-derived exosomes induced the activation of EGFR pathway in both OC progenitors and in MSCs suggests the possibility to use EGFR inhibitors such as erlotinib and gefitinib to impair the cross talk between MM cells and the bone microenvironment and potentially the development of bone lesions.